HCG

Healthcare Global Enterprises Share Price

₹469.15 +1.65 (0.35%)

21 Nov, 2024 14:19

SIP TrendupStart SIP in HCG

Start SIP

Performance

  • Low
  • ₹464
  • High
  • ₹475
  • 52 Week Low
  • ₹314
  • 52 Week High
  • ₹520
  • Open Price₹470
  • Previous Close₹468
  • Volume101,502

Investment Returns

  • Over 1 Month + 6.84%
  • Over 3 Month + 33.24%
  • Over 6 Month + 30.35%
  • Over 1 Year + 32.71%
SIP Lightning

Smart Investing Starts Here Start SIP with Healthcare Global Enterprises for Steady Growth!

Invest Now

Healthcare Global Enterprises Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 114.6
  • PEG Ratio
  • 2.1
  • Market Cap Cr
  • 6,538
  • P/B Ratio
  • 7.9
  • Average True Range
  • 18.22
  • EPS
  • 3.89
  • Dividend Yield
  • 0
  • MACD Signal
  • 10.43
  • RSI
  • 60.51
  • MFI
  • 59.81

Healthcare Global Enterprises Financials

Healthcare Global Enterprises Technicals

EMA & SMA

Current Price
₹469.15
+ 1.65 (0.35%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹456.44
  • 50 Day
  • ₹436.63
  • 100 Day
  • ₹414.74
  • 200 Day
  • ₹391.62

Resistance and Support

468.8 Pivot Speed
  • R3 487.80
  • R2 481.90
  • R1 474.70
  • S1 461.60
  • S2 455.70
  • S3 448.50

What's your outlook on Healthcare Global Enterprises?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Healthcare Global Enterprises Ltd. (HCG) is India’s largest provider of cancer care, operating a network of specialized hospitals across the country. It offers advanced oncology treatments, including radiation, chemotherapy, and surgical oncology, focusing on personalized patient care.

Healthcare Global Ents. has an operating revenue of Rs. 2,043.62 Cr. on a trailing 12-month basis. An annual revenue growth of 13% is good, Pre-tax margin of 4% needs improvement, ROE of 5% is fair but needs improvement. The company has a debt to equity of 59%, which is bit higher. The stock from a technical standpoint is comfortably placed above its key moving averages, around 7% and 22% from 50DMA and 200DMA. From an O'Neil Methodology perspective, the stock has an EPS Rank of 53 which is a POOR score indicating inconsistency in earnings, a RS Rating of 74 which is FAIR indicating the recent price performance, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 30 indicates it belongs to a strong industry group of Medical-Hospitals and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Healthcare Global Enterprises Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-09 Quarterly Results
2024-08-08 Quarterly Results
2024-05-29 Audited Results & ESOP
2024-02-08 Quarterly Results
2023-11-09 Quarterly Results

Healthcare Global Enterprises F&O

Healthcare Global Enterprises Shareholding Pattern

71.23%
8.94%
0.19%
4.3%
9.34%
6%

About Healthcare Global Enterprises

  • NSE Symbol
  • HCG
  • BSE Symbol
  • 539787
  • ISIN
  • INE075I01017

Similar Stocks to Healthcare Global Enterprises

Healthcare Global Enterprises FAQs

Healthcare Global Enterprises share price is ₹469 As on 21 November, 2024 | 14:05

The Market Cap of Healthcare Global Enterprises is ₹6537.5 Cr As on 21 November, 2024 | 14:05

The P/E ratio of Healthcare Global Enterprises is 114.6 As on 21 November, 2024 | 14:05

The PB ratio of Healthcare Global Enterprises is 7.9 As on 21 November, 2024 | 14:05

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23